

Appendix 4D and 31 December Half Year Report

Hydrix Limited ('**Hydrix**' or 'the **Company**') (ASX: **HYD**) today released its Appendix 4D for the six months ended 31 December 2021 (**2Q21**)

First Half Highlights

- Significant increase in total first half revenues (\$5.2million), with the Services business up 41% versus prior comparable period
- Increasing revenues contributed to 50% improvement in bottom line with first half loss from ordinary activities down YoY to \$2.4m
- Strengthened balance sheet to support growth strategy with net proceeds of \$2.7m from a share Placement to sophisticated investors announced 28 February 2022
- Appointed the highly experienced Mr Paul Lewis MBE as Non-Executive Director
- Ventures portfolio indicating future investment returns with a 133% valuation uplift on Cyban Pty Ltd
- The 8th AngelMed Guardian implant completed in Singapore for the first Malaysian domiciled patient
- Submitted regulatory applications in five jurisdictions in S.E. Asia; New Zealand now has WAND approval to commence Guardian implants
- Received independent human research ethics committee approval in Australia to implant The Guardian ahead of TGA approval; and
- Launched a brand new website with immediate inbound lead generation and inquiries.

Hydrix Executive Chairman, Gavin Coote, commented:

The prospect that the cardiac device product business will be a catalyst for growth remains strong. The 18 months of patient data from the 8 Guardian implants and recent implant growth by AngelMed USA, indicates the product is well beyond proof of concept.

The Hydrix Services business showed strong signs of an emerging business recovery with first half revenue growth of +40%. Continued revenue growth will return that business to profitability.

The potential ventures valuation growth in the next one to two years suggests the portfolio returns may well be larger than Hydrix's current market value.

We continue to evaluate other cardiovascular technologies to expand our business, and which are revenue and earnings accretive.

Hydrix Medical

The Guardian

In Singapore, Dr Leslie Lam performed his 8th Guardian implant, this time for a Malaysian national from Johor Bahru (adjacent to Singapore). This is an important milestone for the Guardian technology in Malaysia where we are waiting on regulatory approvals in Singapore and Malaysia.

Singaporean recipients of Guardian devices are advising the Guardian is improving their quality of life. For several patients, The Guardian has set-off 'See Doctor' and 'Emergency' alarms after detecting abnormal heart rhythms leading to timely clinician intervention and identification of symptoms which may have otherwise gone undetected. Based on improved patient specific data from The Guardian, some of those patients have had adjustments to their medications to help better manage their condition.

In Australia, we are currently preparing final stages for Guardian approvals and implants under trial conditions in two private medical centres, working with a private cardiology group in Melbourne.

Every 10 minutes one Australian has a heart attack. Each day 170 Australians are admitted to hospital having had a heart attack, and sadly, 20 Australians die each day as a result of. Data shows that almost half of all heart attacks are silent, whereby the patient either has no symptoms or no recognisable symptoms. The Guardian has been shown to get patients to emergency care 8x faster than patient recognisable symptoms alone and to significantly improve patient quality of life.

Phyzhon Health

With restrictions lifting both in the US and Australia, we are resuming planning for first in human trials of the Phyzhon FFR system coronary guidewire in Melbourne, to be scheduled at a major hospital.

The Hydrix team is also collaborating with Phyzhon on planning and maturing go-to-market strategy for the technology. We will be exhibiting and demonstrating both the Guardian and Phyzhon devices at the 70th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand (CSANZ), later in CY22.

Hydrix Services Update

The Hydrix Services business achieved 40% revenue growth versus prior comparable period, with more than 50% of revenues to come from outside Australia this year. The growth in European revenues is a result of increased business development focus and strategic marketing activities. Our LUDO cardiac-assist-device development platform has proved valuable to existing and prospective clients in this key cardiovascular technologies market segment. We will be demonstrating LUDO at the Hydrix booth at the American College of Cardiology (ACC) 71st Annual Scientific Session & Expo, in Washington DC, April 2 – 4, 2022.

Hydrix Ventures

Our venture investment companies are approaching significant valuation inflection points. The outlook for all four client companies suggests strong valuation returns for Hydrix over the coming years. Highlights from the first half include:

- Participated in the Cyban Series A capital raise, completed at greater than 2X investment uplift
- Memphis announced their maiden commercial sale of their Felix platform and collaboration with Monash IVF to support regulatory applications.
- Significant progress continues towards completion of major milestones in the Product Development and Verification of the GYDER® Hip Navigation System
- AngelMed USA received a TPT reimbursement Code effective 1 January 2022, having completed more than 40 implants since receiving **FDA approval in June 2021** of the 2nd Generation system.

Outlook and Potential News Flow over the next 6-to-12 months includes:

- FY22 full year-on-year client services revenue growth
- Uplift in valuations across the Ventures portfolio as inflection milestones are achieved
- Updates re AngelMed Guardian regulatory approvals in Australia, Singapore and Malaysia
- First implants of AngelMed Guardian in Australia & New Zealand
- Commencement of First-in-Human study of Phyzhon FFR system coronary guidewire
- Cash inflows of up to \$2.25m from HYDO \$0.12c options, if exercised (expire 31/7/22); and
- Potential outcomes from ongoing evaluations of strategic growth initiatives.

-ENDS-

Authorisation: This announcement is authorised for release by the Board of Directors of Hydrix Limited.

Contact Details: For more information, please contact:

Company Enquiries:

Gavin Coote

Executive Chairman

info@hydrix.com

+61 3 9550 8100

Media Enquires:

Rod North

Managing Director, Bourse Communications

rod@boursecommunications.com.au

+61 3 9510 8309

About Hydrix Limited

Hydrix Limited (ASX: HYD) is a powerful product innovation company. Hydrix purpose is to enhance the health, safety, and wellbeing of 1 billion lives. The company leverages its powerful product innovation capability across multiple growth platforms. These platforms include **Hydrix Services** design and engineering to create products which transform markets; **Hydrix Ventures** to pick winning investments in high potential innovative products; and **Hydrix Medical** to create new product revenue streams bringing cardiovascular technologies to market which improve patient mobility and quality of life.